Lantern Pharma shares jumped over 30% to $1.45 in pre-market trading after the company and subsidiary Starlight Therapeutics announced the FDA had cleared an investigational filing (article text truncated). The FDA clearance is a positive regulatory milestone for this clinical-stage biotech and has already produced a sizable re-rating of the equity.
Lantern Pharma shares jumped over 30% to $1.45 in pre-market trading after the company and subsidiary Starlight Therapeutics announced the FDA had cleared an investigational filing (article text truncated). The FDA clearance is a positive regulatory milestone for this clinical-stage biotech and has already produced a sizable re-rating of the equity.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.60
Ticker Sentiment
